Fundraising FoxKIROMIC BIOPHARMA INC
Defunct1 known investors
Find your way into KIROMIC BIOPHARMA INC
Sign up to find every way you can get introduced to KIROMIC BIOPHARMA INC
- Your email: who you already know at KIROMIC BIOPHARMA INC, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the KIROMIC BIOPHARMA INC team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Kiromic BioPharma was a clinical-stage biotherapeutics company using an AI-driven platform to develop allogeneic Gamma Delta T-cell immunotherapies for solid tumors, including lead candidate Deltacel-01 for lung cancer.
Investors · 1
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $850.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $226.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $222.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does KIROMIC BIOPHARMA INC do?
- Kiromic BioPharma was a clinical-stage biotherapeutics company using an AI-driven platform to develop allogeneic Gamma Delta T-cell immunotherapies for solid tumors, including lead candidate Deltacel-01 for lung cancer.
- Who are KIROMIC BIOPHARMA INC's investors?
- KIROMIC BIOPHARMA INC's investors include Sofinnova Ventures.